Voluntary isn't working
By Marcy Darnovsky,
Modern Healthcare
| 04. 13. 2009
Recent events show need for regulation of assisted reproduction
Each year, assisted reproduction quietly helps thousands of people in their quest for children biologically related to them. But the fertility field has been far from quiet of late. In recent weeks, two scandals burst into the headlines
The first stories about the Southern California octuplets, in late January, focused on the novelty and details of their birth. But shock and then outrage quickly followed as news of the mother's circumstances and the fertility doctor's recklessness emerged. Entertainment news has yet to tire of the story; a more sober conversation about the need for additional policy and oversight is also simmering.
A few weeks later, the Wall Street Journal reported that another Los Angeles-area fertility clinic had begun advertising the "pending availability" of embryo screening to select for hair color, eye color and even skin tone. As that story bubbled into network and cable news, it elicited a reaction similar to the one surrounding the octuplets: What's going on here? How can irresponsible fertility doctors get away with this sort of thing?
These questions are not being asked only by...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...